3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15

Developing a technology that enables oral vaccines to work efficiently remains a considerable effort since a number of difficulties must be addressed. The key objective being to ensure the safe passage through the harsh conditions within the gastrointestinal tract, promoting delivery that induces enhanced immune response. In the particular case of hepatitis B, the oral formulation in the nanostructured silica SBA-15 is a viable approach. As a result of its porous structure, low toxicity and structural stability, SBA-15 is capable to protect and release the hepatitis B surface antigen (HBsAg), used in the vaccination scheme, at the desired destination. Furthermore, when compared to the currently used injection based delivery method, better or similar antibody response has been observed. However, information about the organisation of the antigen protein remains unknown. For instance, HBsAg is too large to enter the 10 nm ordered mesopores of SBA-15 and has a tendency to agglomerate when protected by the delivery system. Here we report on the pH dependence of HBsAg aggregation in saline solution investigated using small angle X-rays scattering that resulted in an optimisation of the encapsulation conditions. Additionally, X-ray microscopy combined with neutron and X-ray tomography provided full 3D information of the HBsAg clustering (i.e. agglomeration) inside the SBA-15 macropores. This method enables the visualisation of the organisation of the antigen in the interior of the delivery system, where agglomerated HBsAg coexists with its immunological effective uniformly distributed counterpart. This new approach, to be taken into account while preparing the formulation, can greatly help in the understanding of clinical studies and advance new formulations.

[1]  Sylvain Bohic,et al.  ID16B: a hard X-ray nanoprobe beamline at the ESRF for nano-analysis , 2016, Journal of synchrotron radiation.

[2]  T. Kumasaka,et al.  Protein encapsulation within synthetic molecular hosts , 2012, Nature Communications.

[3]  André Hilger,et al.  CONRAD-2: Cold Neutron Tomography and Radiography at BER II (V7) , 2016 .

[4]  V. Botosso,et al.  Nanostructured SBA-15 silica as an adjuvant in immunizations with hepatitis B vaccine. , 2011, Einstein.

[5]  U. Frommherz,et al.  Higher Order Suppressor (HOS) for the PolLux microspectroscope beamline at the Swiss Light Source SLS , 2010 .

[6]  S. Gabrielsson,et al.  Mesoporous silica particles potentiate antigen-specific T-cell responses. , 2014, Nanomedicine.

[7]  W. Jiskoot,et al.  Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[8]  D. Tambourgi,et al.  Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. , 2010, Vaccine.

[9]  H. Gies,et al.  Protein encapsulation in mesoporous silicate: the effects of confinement on protein stability, hydration, and volumetric properties. , 2004, Journal of the American Chemical Society.

[10]  R. Zare,et al.  One-pot synthesis of protein-embedded metal-organic frameworks with enhanced biological activities. , 2014, Nano letters.

[11]  D I Svergun,et al.  Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. , 1999, Biophysical journal.

[12]  M. Fantini,et al.  Physical properties of ordered mesoporous SBA-15 silica as immunological adjuvant , 2014 .

[13]  C. Carucci,et al.  Significant Enhancement of Structural Stability of the Hyperhalophilic ADH from Haloferax volcanii via Entrapment on Metal Organic Framework Support. , 2018, Langmuir : the ACS journal of surfaces and colloids.

[14]  Z. Su,et al.  Aggregation and antigenicity of virus like particle in salt solution--A case study with hepatitis B surface antigen. , 2015, Vaccine.

[15]  I. Berkower,et al.  Hepatitis B Virus Surface Antigen Assembly Function Persists when Entire Transmembrane Domains 1 and 3 Are Replaced by a Heterologous Transmembrane Sequence , 2010, Journal of Virology.

[16]  Robert Langer,et al.  The biocompatibility of mesoporous silicates. , 2008, Biomaterials.

[17]  J. García de la Torre,et al.  Prediction of hydrodynamic and other solution properties of rigid proteins from atomic- and residue-level models. , 2011, Biophysical journal.

[18]  H. Ade,et al.  The PolLux Microspectroscopy Beam line at the Swiss Light Source , 2007 .

[19]  David F. Williams Biofunctionality and Biocompatibility , 2006 .

[20]  J. Banhart,et al.  CONRAD-2: the new neutron imaging instrument at the Helmholtz-Zentrum Berlin , 2016 .

[21]  Paulo R. A. F. Garcia,et al.  Nanostructured SBA-15 silica: An effective protective vehicle to oral hepatitis B vaccine immunization. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[22]  T. Tyliszczak,et al.  PolLux: a new facility for soft x-ray spectromicroscopy at the Swiss Light Source. , 2008, The Review of scientific instruments.

[23]  Shengqian Ma,et al.  Immobilization of MP-11 into a mesoporous metal-organic framework, MP-11@mesoMOF: a new platform for enzymatic catalysis. , 2011, Journal of the American Chemical Society.

[24]  C. L. Oliveira Investigating Macromolecular Complexes in Solution by Small Angle X-Ray Scattering , 2011 .

[25]  T. Tyliszczak,et al.  Spatially resolved NEXAFS spectroscopy of siderophores in biological matrices , 2013 .

[26]  S. Gabrielsson,et al.  Adjuvant properties of mesoporous silica particles tune the development of effector T cells. , 2012, Small.

[27]  Robyn P. Seipp,et al.  MUCOSAL IMMUNITY AND VACCINES , 2013 .

[28]  Bradley F. Chmelka,et al.  Nonionic Triblock and Star Diblock Copolymer and Oligomeric Surfactant Syntheses of Highly Ordered, Hydrothermally Stable, Mesoporous Silica Structures , 1998 .

[29]  Myron M Levine Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine , 2010, BMC Biology.

[30]  I. D. Morrison,et al.  Improved techniques for particle size determination by quasi-elastic light scattering , 1985 .

[31]  Eric C. Carnes,et al.  Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. , 2013, Accounts of chemical research.

[32]  N. Petrovsky Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs , 2015, Drug Safety.

[33]  M. Jaroniec,et al.  Ordered mesoporous silica SBA-15: a new effective adjuvant to induce antibody response. , 2006, Small.

[34]  Samir Mitragotri,et al.  Macrophages Recognize Size and Shape of Their Targets , 2010, PloS one.

[35]  E. Lavelle,et al.  Delivery strategies to enhance oral vaccination against enteric infections. , 2015, Advanced drug delivery reviews.

[36]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. , 2008, Advanced drug delivery reviews.

[37]  V. Botosso,et al.  Dynamics of encapsulated hepatitis B surface antigen , 2019, The European Physical Journal Special Topics.

[38]  H. Kiyono,et al.  Mucosal vaccines: novel advances in technology and delivery , 2009, Expert review of vaccines.

[39]  Fredrickson,et al.  Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores , 1998, Science.

[40]  P. Duringer,et al.  Ultrastructural and chemical study of modern and fossil sporoderms by Scanning Transmission X-ray Microscopy (STXM) , 2009 .